STOCK TITAN
  1. Home
  2. News
  3. MRNS

Marinus Pharmaceuticals Inc - MRNS STOCK NEWS

Welcome to our dedicated news page for Marinus Pharmaceuticals (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marinus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marinus Pharmaceuticals's position in the market.

News
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Rhea-AI Summary
Marinus Pharmaceuticals provides an update on the Phase 3 RAISE trial and reports preliminary first quarter 2024 financial results. The trial did not meet pre-defined stopping criteria at the interim analysis, with topline results expected in summer 2024. The company plans to assess the future development of IV ganaxolone in refractory status epilepticus based on the final RAISE results. Enrollment in the TrustTSC trial is expected to be completed in mid-May, with topline data on track for the first half of Q4 2024. Cost reduction activities are under review to extend cash runway, with preliminary Q1 2024 net product revenue of $7.4-$7.6 million and cash equivalents of $113.3 million as of March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.71%
Tags
earnings clinical trial
-
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) granted inducement awards to two new employees, issuing 47,400 stock options at an exercise price of $8.68 per share. The options vest over time, with 25% becoming exercisable after one year and the remaining 75% vesting in 36 monthly installments. The awards aim to attract and retain talent, aligning with Nasdaq regulations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
-
News
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Rhea-AI Summary
Marinus Pharmaceuticals reaffirms its commitment to defending its patent portfolio amidst an IPR challenge by Ovid Therapeutics related to the use of ganaxolone in treating seizure disorders. Marinus has invested over $100 million in ganaxolone development programs, yielding a strong patent portfolio supported by robust clinical data. The company believes the challenge is without merit and vows to vigorously defend its patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
News
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) provides a business update and financial results for the year ended December 31, 2023. The company has commenced ReMEDy2 clinical site activation and strengthened its management team. With $53 million in cash, DiaMedica has runway till 2026. The ReMEDy2 Phase 2/3 AIS clinical developments are progressing well with multiple sites opened in the U.S. and plans for global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) achieves Phase 3 RAISE trial enrollment target, expects topline results in Q2 2024. ZTALMY® (ganaxolone) nets $6.6 million in Q4 2023 and $19.6 million in 2023. Cash runway into Q4 2024 with $150.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
earnings
-
News
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) will be presenting at the TD Cowen 44th Annual Healthcare Conference and the Leerink Partners 2024 Global Biopharma Conference in March. The company is dedicated to developing innovative therapeutics for seizure disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences
News
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) will release its financial results for Q4 and full year 2023 on March 5, 2024, followed by a conference call. The company focuses on developing therapeutics for seizure disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
earnings
-
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. announced the grant of inducement awards to four new employees, involving non-qualified stock options for 64,425 shares of Common Stock at an exercise price of $10.21 per share. The stock options will vest over time, with 25% becoming exercisable after one year and the remaining 75% in 36 monthly installments, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) appoints Dr. Lorianne Masuoka, a board-certified neurologist with over 25 years of experience, as Chief Medical Officer. Dr. Masuoka has a successful track record in managing clinical programs and progressing the development of therapeutics for neurological disorders. The company granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
management
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) announced the grant of inducement awards to a new employee, approving the grant of non-qualified stock options to purchase 12,150 shares of its common stock. The stock options have an exercise price of $10.40 per share and will vest over time, subject to the employee's continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
Stock MRNS logo
Marinus Pharmaceuticals Inc

Nasdaq:MRNS

MRNS Rankings

#4448 Ranked by Market Cap
#1099 Ranked by Stock Gains
N/A Ranked by Dividends

MRNS Stock Data

413.08M
42.76M
1.57%
98.62%
6.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Radnor

About MRNS

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides